Close

Tevogen Bio, BioCentriq Partner for COVID T-cell Therapy

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

How To Select A CDMO: Focus On Client-Centered Approach

When it comes to the pharmaceutical sector, choosing the...

Tevogen Bio has entered a partnership with BioCentriq, a New Jersey based cell and gene therapy development and manufacturing center, to support clinical manufacturing of Tevogen’s investigational COVID-19 treatment.

Both partners will collaborate at BioCentriq’s state-of-the art GMP facilities to produce Tevogen’s proprietary COVID-19 targeted T cells. The teams will leverage processes and technology required to ensure quality standards are met in the large scale manufacturing of Tevogen’s clinical grade, allogeneic T-cell therapy.

“Our team of experts will work collaboratively with Tevogen to apply best practices, advanced technologies and proven analytical methods to prepare them for clinical trials and beyond,” said Haro Hartounian, Ph.D., senior vice-president, and general manager of BioCentriq. “We are proud to partner with a New Jersey based biotechnology company that is advancing highly promising investigational curative therapy by leveraging lab-grown virus-specific t-lymphocytes to recognize and destroy COVID-19-infected cells.”

Tevogen’s IND application for its antigen specific T cell therapy is currently under review by the U.S. FDA. In the upcoming trials, Tevogen will study its highly enriched COVID-19 specific CD8+ T cells, TVGN-489, for the drug’s safety and ability to recognize and eliminate COVID-19 infected cells, essentially curing a patient of the virus.

Latest stories